Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: A nationwide, multicenter study (American Journal of Gastroenterology (2009) 104, (57-63) DOI: 10.1038/ajg.2008.4);Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: A nationwide, multicenter study

American Journal of Gastroenterology

Volumn 104, Issue 1, 2009, Pages 57-63

  Loras, Carme ^a   Saro, Cristina ^b   Gonzalez Huix, Ferrn ^c   Mínguez, Miguel ^d   Merino, Olga ^e   Gisbert, Javier P ^f   Barrio, Jess ^g   Bernal, Antonio ^h   Gutiérrez, Ana ⁱ   Piqueras, Marta ^j   Calvet, Xavier ^k   Andreu, Montserrat ^l   Abad, Agueda ^m   Ginard, Daniel ⁿ   Bujanda, Luis ^o   Panés, Julián ^k   Torres, Miquel ^p   Fernández Bãares, Fernando ^a   Viver, Josep M ^a   Esteve, Maria ^a,q  

^a Hospital Mtua de Terrassa   (Spain)

^b Department of Gastroenterology   (Spain)

^c Department of Gastroenterology   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^h HOSPITAL DE GALDAKAO   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^j HOSPITAL DE TERRASSA   (Spain)

^k INSTITUTO DE SALUD CARLOS III   (Spain)

^l HOSPITAL DEL MAR   (Spain)

^m Hospital de Sant Llorenç   (Spain)

ⁿ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^o UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^p Hospital de LEsperit Sant   (Spain)

^q UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; IMMUNOSUPPRESSIVE AGENT; STEROID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD BANK; BLOOD TRANSFUSION; COLITIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ABUSE; ENTERITIS; FAMILY HISTORY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INVASIVE PROCEDURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; SPAIN; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS; VACCINATION; VIRUS INFECTION; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MULTICENTER STUDY; VIROLOGY;

ADOLESCENT; ADULT; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PREVALENCE; SPAIN; YOUNG ADULT;

EID: 60749113827     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.96     Document Type: Erratum

References (36)

1. Biancone L, Pavia M, Del Vecchio Blanco G et al. Italian Group for the Study of the Colon and Rectum (GISC). Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001;7:287-94.
2. Bargiggia S, Thorburn D, Anderloni A et al. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther 2005;22:209-15.
3. Longo F, Hebuterne X, Tran A et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol 2000;24:77-81.
4. Forns X, Martínez-Bauer E, Feliu A et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology 2005;41:115-22.
5. Salcedo-Mora X, Maté J, Medina J et al. Chronic hepatitis C and Crohn's disease: nosocomial infection treatment with PEG-interferon plus ribavirin. Digestion 2006;73:210-14.
6. Esteve M, Saro C, González-Huix F et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5.
7. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333-40.
8. Ostuni P, Botsios C, Punzi L et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7.
9. Michel M, Duvoux C, Hezode C et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003;30:1624-5.
10. Oniankitan O, Duvoux C, Challine D et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9.
11. del Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A et al. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004;10:701-2.
12. Ueno Y, Tanaka S, Shimamoto M et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005;50: 163-6.
13. Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005;64:788-9.
14. Millonig G, Kern M, Ludwiczek O et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-6.
15. Madonia S, Orlando A, Sdmeca D et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9.
16. Esteve M, Loras C, González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007;13:1450-51.
17. Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001:13:191-2.
18. Biancone L, Del Vecchio Blanco G, Pallone F, et al., Italian Group for the Study of the Colon and Rectum. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002;122:593-4.
19. Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003;98:504-5.
20. Peterson JR, Hsu FC, Simkin PA et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82.
21. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800-4.
22. Roux CH, Brocq O, Breuil V et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006;45:1294-7.
23. Aslanidis S, Vassiliadis T, Pyrpasopoulou A et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007;26:261-4.
24. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
25. Shouval D. Hepatitis B vaccines. J Hepatol 2003;39 (Suppl 1): S70-6.
26. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 (Suppl A): 5-36.
27. Sola R, Cruz De Castro E, Hombrados M et al. Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study. Med Clin (Bare) 2002;119:90-5.
28. Garcia Fulgueiras A, Tormo A, Rodriguez T et al. Prevalence of hepatitis B and C markers in the southeast of Spain: an unlinked community based serosurvey of 2,203 adults. Scand J Infect Dis 1996;28:17-20.
29. Suarez A, Viejo G, Navascues CA et al. The prevalence of hepatitis A, B and C viral markers in the population of Gijón between 26 and 65 years old. Gastroenterol Hepatol 1997;12:347-52.
30. Riestra S, Fernández E, Leiva P et al. Prevalence of hepatitis C virus infection in the general population of the northern Spain. Eur J Gastroenterol Hepatol 2001;13:477-81.
31. Salleras L, Domínguez A, Bruguera M et al. Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination. Vaccine 2007;25:8726-31.
32. Melmed GY, Ippoliti AF, Papadakis KA et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834-40.
33. Iannitto E, Minardi V, Calvaruso G et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005;74:254-8.
34. Law JK, Ho JK, Hoskins PJ et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085-9.
35. Raimondo G, Navarra G, Mondello S et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008;48: 743-6.
36. Manzini P, Girotto M, Borsotti R et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007;92:1664-70.